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Gamma oscillatory activity in vitro: a model
system to assess pathophysiological
mechanisms of comorbidity between
autism and epilepsy
D. Subramanian1, E. Pralong2, R. T. Daniel2, A. G. Chacko1, R. Stoop3 and K. S. Babu1
Abstract
Autism spectrum disorder (ASD) and temporal lobe epilepsy exhibit remarkable comorbidity, but for reasons not
clearly understood. To reveal a common pathophysiological mechanism, we here describe and characterize an in vitro
epileptiform activity in the rat hippocampus that exhibits common features with in vivo activity in rodent ASD models.
We discovered the development of this activity in the CA1 region of horizontal slices after prolonged interictal-like
epileptiform activity in the CA3 region that was provoked by incubation in high potassium artiﬁcial cerebrospinal ﬂuid.
The CA1 epileptiform bursts were insensitive to blockers of glutamatergic transmission, and were carried by synaptic as
well as extrasynaptic, tonically activated gamma-aminobutyric acid type A (GABA(A)) receptors. The bursts bear
resemblance to in vivo gamma-oscillatory activity found in rat ASD models with respect to their gamma frequency
spectrum, their origin (in the CA1), and their sensitivity to blockers of cation-chloride pumps (NKCC1 and KCC2), as well
as to oxytocin. Considering this bursting activity as an in vitro model for studying comorbidity between epilepsy and
ASD may help to disentangle the intricate interactions that underlie the comorbidity between both diseases and
suggests that extrasynaptic tonic GABAergic transmission could represent a potential target for ASD.
Introduction
Epilepsy and autism spectrum disorder (ASD) are
developmental disorders that exhibit a high degree of
comorbidity and for which, despite decades of research,
effective treatments are still lacking1–3. The increased
prevalence of clinical epilepsy and paroxysmal electro-
encephalographic (EEG) epileptiform activity in patients
with ASD has led to the belief that ASD and epilepsy
might have a partially common underlying brain pathol-
ogy2. Although their comorbidity could be caused at the
level of the chromosome or by co-occurring environ-
mental inﬂuences, recent ﬁndings rather suggest a
common pathophysiological mechanism at the level of
neuronal circuits as underlying cause1.
One possible common mechanism underlying ASD and
epilepsy may be found in an early excitation/inhibition
imbalance in the brain4–6. ASD has been postulated to be
caused by a reversal of gamma-aminobutyric acid type A
(GABA(A)) receptor-mediated neurotransmission from
inhibition to excitation as a result of an increased intra-
cellular Cl− concentration ([Cl−]i) that would result in
reduced inhibition in the ASD brain5,7,8. Such disruptions
in Cl− homeostasis have indeed been reported in both
humans and animal models of autism7,9–11. Consequently,
drug interventions targeting the cation-chloride co-
transporters within the CA1/CA3 region of the hippo-
campus have been able to rescue ASD-associated changes
in intracranially recorded gamma oscillations as well as
behavioral expressions such as ultrasonic vocalizations5,12.
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Among these are the diuretic bumetanide and, more
recently, oxytocin, a naturally occurring neuropeptide that
shows promise for the treatment of autism9,10,12.
We therefore based our present approach on the
assumption that the disruption of the chloride equili-
brium potential can also underlie epileptic patholo-
gies13,14 and can thus constitute a basis for a common
pathophysiological mechanism. To test this hypothesis,
we developed a rodent in vitro model of epileptiform
activity which we characterized in close comparison with
established in vivo recordings from rodent ASD models
and on which we compared effects of pharmacological
interventions already employed in ASD. We found a
bursting activity in the CA1 hippocampal region that was
primarily driven by GABA(A) receptor activation and that
exhibited strong 40 Hz components which closely
resembled atypical gamma oscillations observed in in vivo
animal models of ASD. We validated our model by testing
pharmacological treatments that are efﬁcient in animal
models of ASD. Our ﬁndings revealed a new anti-
convulsant potential for oxytocin and, in addition, we
found that extrasynaptic GABAergic transmission appears
to underlie these epileptiform bursts which may thus
point to new potential targets for epilepsy and ASD.
Materials and methods
Animals
All procedures were conducted in accordance with the
guidelines of the Committee for the Purpose of Control
and Supervision of Experiments on Animals and were
approved by the Institutional Review Board and Institu-
tional Animal Ethics Committee of Christian Medical
College, Vellore.
Slice preparation
After anesthesia with isoﬂurane and decapitation, brains
from 4 to 8 weeks Wistar rats were removed quickly and
placed in ice-cold cutting solution containing (in mM):
110 sucrose, 60 NaCl, 3 KCl, 0.5 CaCl2, 7 MgSo4, 26
NaHCO3, 1.2 NaH2PO4, 5 glucose at pH 7.4, and oxyge-
nated with 95% O2/5% CO2. Horizontal slices of the
ventral hippocampus (450 µm thick, see Stoop and Pra-
long15) were cut using a vibratome (VF200, Precisionary
instruments, USA) and perfused in an interface chamber
for 1 h or more at 24–26 °C in a solution of artiﬁcial
cerebrospinal ﬂuid (aCSF) containing (in mM) 124 NaCl,
3.5 KCl, 2 CaCl2, 2 MgSO4, 26 NaHCO3, 1.2 NaH2PO4,
and 10 glucose at a rate of 1 ml/min. A ﬁne needle (31 G)
was used for dissecting out entorhinal cortex (EC) before
induction of epileptiform events and for disconnecting
Schaffer collateral (SC) projections from CA3 to CA1, or
for preparing CA1 mini-slices by isolating CA1 between
CA3 and the subiculum.
Electrophysiological recordings and induction of
epileptiform events
Field potentials were recorded from the stratum pyr-
amidale of CA3a and CA1 subﬁelds using aCSF ﬁlled
microelectrodes (~ 1MΩ). Recorded signals were ampli-
ﬁed 10,000 times, band pass ﬁltered between 1 and 1000
Hz (Model 1800, AM Systems, USA), and digitized at 5
kHz (PCle 6321-DAQ-National Instruments, USA), using
custom-written codes for LabView (Ver-10.0, National
Instruments). Ten minutes of baseline were recorded
before any intervention and data were further ﬁltered
between 1 and 100 Hz during analysis. Incubation in aCSF
with 8.5 mM KCl and 1.2 mM CaCl2 and MgSO4 at 34–36
°C (TC-344B Dual automatic temperature controllers,
Warner Instruments, USA) produced epileptiform events
that were identiﬁed and classiﬁed as (i) interictal-like
epileptiform discharges (hereafter referred as interictal
discharges) and (ii) ictal-like epileptiform discharges
(hereafter referred as IEDs) based on their duration and
appearance as described by Dzhala and Staley16.
Statistics and analysis
Sample size was determined prior to experiments to
achieve a power of 0.80 and a probability of type I error
(α) of 0.05. Parameters studied included number of
spikes/event, peak amplitude, burst duration, spike fre-
quency, interburst interval, and power of gamma oscilla-
tions. Slices showing spreading depression were excluded
from the study since they can affect the parameters
evaluated. For event detection, burst, and spectral analysis
we used Clampﬁt (Molecular Devices, USA). Bursts were
grouped together based on their inter-spike intervals ( o
500 ms). Results are presented as mean or normalized
percentage difference± standard error of mean (SEM).
For statistical analysis, paired and unpaired two-tailed
Student's t test was used. Signiﬁcance was assigned at p
o 0.05.
Chemicals
Bicuculline methiodide (BMI), picrotoxin, SKF 89976A,
and aCSF ingredients originated from Sigma-Aldrich (St.
Louis, MO, USA); 2,3-dioxo-6-nitro-1,2,3,4- tetra-
hydrobenzo[f]quinoxaline-7-sulfonamide disodium salt
(NBQX), D-AP5, bumetanide, CLP257, and VU 0463271
from Tocris Bioscience (Bristol, UK); [Thr4, Gly7] oxy-
tocin (TGOT) and (d(CH2)51,Tyr(Me)2,Thr4,Orn8,des-
Gly-NH29)-vasotocin (vasotocin) from American Peptide
Company (Sunnyvale, CA, USA).
Results
We found that within 40–60min of exposure to aCSF
with high K+, “seizure onset” in both CA3 and CA1 (Fig.
1a1) was followed by typical interictal-like discharges (Fig.
1a2, 0.67± 0.08 mV amplitude, 22.8± 2.4 s intervals) that
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progressed into IEDs. These latter consisted of an initial
period of sustained discharges (“ictal tonic”, Fig. 1a3, 1.1
± 0.15 mV, 8.6± 0.8 s), followed by intermittent dis-
charges (“ictal clonic”, Fig 1a4, 1.5± 0.2 mV, 66.3± 8.6 s).
Complete IEDs consisted of 361± 10.3 discharges that
lasted 112± 2.4 s and occurred at intervals of 186± 3.8 s.
They seemed to progress from CA3 with 15.2± 1.4 s delay
between seizure onset to CA1 (Fig. 1a1).
Upon prolonged incubation in high K+ aCSF (460
min), we found a new type of bursts in the CA1 that
preceded the IEDs. These CA1 bursts were of high fre-
quency, short duration (4.2± 0.8 s), and consisted of 75±
13 population spike discharges with a peak amplitude of
1.3± 0.2 mV (n= 60 slices, 44 animals). They developed
exclusively in the CA1 region and not only preceded
interictal discharges and IED’s in the CA1 (by 8.9± 1 s),
but also those in the CA3 region (Fig. 1b, right lower
panel). To investigate if these CA1 bursts affected initia-
tion of epileptiform events in CA3, we recorded ﬁeld
potentials simultaneously from CA3, CA2, and CA1.
Although an increase in baseline activity was evident in
CA2 (delay of 2± 0.3 s, Fig. 4a) and CA3 (delay of 8.6±
1.3 s), we could not conclusively determine such inﬂuence
since properties of CA3 discharges appeared unaltered
Fig. 1 High K+ aCSF induced epileptiform discharges in hippocampal slices. a Trains of epileptiform discharges are seen in CA3 and CA1 within
40–60 min of incubation (n = 34 slices from 27 animals). A single epileptiform event and its different phases are shown expanded in time1–4. b
Prolonged incubation in high K+ aCSF leads to the development of CA1 gamma bursts (n = 60 slices from 44 animals) subsets below show the
initiation of epileptiform event before (left) and after the development of gamma bursts. Note the gamma bursts appearing in CA1 before initiation
of epileptiform activity in CA3
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after the CA1 bursts developed (data not shown). Detailed
spectral analysis of the CA1 bursts revealed a strong
gamma frequency component (34.9± 1.7 Hz, Fig. 2), and
we henceforth refer to these as “gamma bursts”.
To examine the origin of these gamma bursts, we sev-
ered SC projections to the CA1 with the tip of a ﬁne 31 G
needle. Although this completely abolished IED’s in the
CA1 region, it did not affect the gamma bursts (Fig. 3a). In
fact, gamma bursts now appeared more often at shorter
Fig. 2 Spectrogram of CA1 ﬁeld recordings during the development of CA1 gamma bursts. a–d The transition in initiation of epileptiform events in
CA1 of the same slice at intervals of 5 min. The arrows denote the peak activation during gamma bursts which was mostly seen around 30–40 Hz
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intervals (53.2± 1.3 s compared to 186± 3.8 s, Fig. 3a, d;
p o 0.001, n= 14 slices, 10 animals). To further investi-
gate if CA3 inputs are required for the initial development
of gamma bursts, we prepared, before incubation in high
K+ aCSF, isolated slices of the CA1, and henceforth
referred to as “CA1 mini-slices” (Fig. 3b). In these
CA1 mini-slices, gamma bursts appeared within 30min of
incubation without prior development of IEDs. Although
in some mini-slices gamma bursts were followed by a
series of after-discharges (see example Fig. 4b, top traces),
in all other respects these gamma bursts exhibited similar
characteristics as gamma bursts that had developed in
intact slices in which SCs were severed (see Table 1 for
spikes/burst, spike frequencies, peak amplitudes, burst
intervals, and duration).
To further examine their pharmacological sensitivity,
we blocked glutamate transmission in intact slices with
NBQX (10 μM) and D-AP5 (50 μM). Although this com-
pletely abolished IEDs in CA3 and CA1, it did not block
the generation of CA1 gamma bursts. Instead, similar to
anatomical disconnection of SC, it signiﬁcantly shortened
the intervals between consecutive gamma bursts (from
189.4± 15.8 to 88± 4.9 s, Fig. 3c, e). Furthermore, NBQX
+AP5 also signiﬁcantly increased the average spikes/
burst, burst duration, and amplitude (see Table 1). Similar
effects of NBQX+D-AP5 were found in CA1 mini-slices
(Fig. 5a, Table 1). In summary, these experiments show
that gamma bursts do not depend on glutamatergic
synaptic transmission, and that they are generated and
can develop in the CA1 independently from CA3 inputs.
To identify the precise origin of the gamma bursts
within the CA1 subﬁeld, we simultaneously recorded ﬁeld
potentials in CA1a, CA1b, and CA1c in mini-slices. In
most slices (9/14), gamma bursts originated from CA1c
and propagated toward CA1b and CA1a (with delays of
1.7± 0.1 and 3.3± 0.2 s, respectively). In ﬁve slices they
originated from the CA1a region and propagated to the
CA1b (delay of 1.7± 0.2 s) and CA1c (delay of 2.6± 0.3 s;
Fig. 4b). To assess the synaptic nature underlying their
generation, we perfused CA1 mini-slices with high K+
aCSF without calcium. Zero Ca2+ aCSF reversibly abol-
ished gamma bursts (within 16.1± 2min, n= 7 slices
from ﬁve animals, Fig. 4d), conﬁrming a synaptic
mechanism underlying their generation. Furthermore,
application of the gap junction blocker carbenoxalone
(100 µM) did not signiﬁcantly alter the gamma bursts
(data not shown, n= 3). In summary, CA1 gamma bursts
appear synaptically mediated but not by glutamatergic
transmission, they propagate only locally, and exhibit
inherent frequencies (40 Hz) that are higher than typical
IED’s.
The above ﬁndings point to a synaptic transmission that
is rather relying on GABA(A) receptors. We therefore
bath perfused the speciﬁc GABA(A) receptor antagonist
BMI (20 μM) onto CA1 mini-slices with gamma bursts, in
the presence of NBQX and D-AP5 to prevent disinhibi-
tion induced hyperactivity. This combination strongly
suppressed the gamma bursts (see Fig. 5b and Table 2).
We next examined whether GABA-induced depolariza-
tion as a result of changes in chloride equilibrium
potential could underlie the generation of gamma bursts
and for that reason perfused slices with modulators of
NKCC1, inward co-transporter of Na+, K+, and Cl− and
KCC2, outward co-transporter of K+ and Cl−. The
NKCC1 antagonist bumetanide (10 and 50 μM) sig-
niﬁcantly reduced all gamma burst parameters (Fig. 5c, d,
Table 2), but the KCC2 agonist CLP257 had little effect
(Fig. 5e, Table 2). Since it is known that KCC2, under high
extracellular K+ conditions, may allow inﬂux rather than
efﬂux of Cl− ions11,17,18, we instead used the speciﬁc
KCC2 antagonist VU 0463271 (10 μM). This indeed sig-
niﬁcantly decreased burst duration, peak amplitude, and
gamma power, and also increased the interburst interval,
though it also increased somewhat spike frequency (Fig.
5f, see Table 2 for comparison). Taken together, these
ﬁndings suggest that the gamma bursts are carried by
GABA(A) receptor-mediated synaptic transmission that
has become excitatory as a result of high extracellular K+.
High extracellular K+ may also alter functioning of the
neuronal GABA transporter GAT-1 causing it to operate
in reverse and, instead of uptake, induce non-vesicular
release of GABA19,20. The ensuing increase in ambient
GABA levels in the extracellular space could enhance
tonic conductance through extrasynaptic GABA recep-
tors21,22. Tonic activation of such GABA(A) receptors
would lead to a steady inﬂow of Cl− and the resulting
increase in [Cl−]I
23 could underlie the development of
excitatory GABAergic gamma bursting. We studied the
involvement of extrasynaptic GABA receptors in gamma
burst development by applying picrotoxin at a low con-
centration (1 μM) at which it is known to only block
extrasynaptic GABA receptors24. At this concentration,
picrotoxin also strongly suppressed gamma bursts and led
to a signiﬁcant reduction in all the parameters studied
(Fig. 5g, Table 2). Moreover, to determine if a reversal of
GAT-1 transporter played a role in gamma burst gen-
eration, the speciﬁc GAT-1 blocker SKF89976A hydro-
chloride (SKF, 40 μM) was applied to CA1 mini-slices
showing gamma bursts. It irreversibly abolished all
gamma bursts within 50± 10.2 min of application (Fig. 5j,
Table 2).
Recently, it has been shown that oxytocin, a naturally
occurring neuropeptide, can alter [Cl−]i accumulation in
immature rats by inhibiting NKCC1 during delivery10 and
by modulating the insertion of KCC225. We therefore also
tested oxytocin and found that application of the speciﬁc
oxytocin agonist TGOT (0.4 µM) signiﬁcantly reduced all
parameters of the gamma bursts (Fig. 5h, Table 2). This
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Fig. 3 (See legend on next page.)
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Fig. 3 Anatomical and pharmacological isolation of CA1 from CA3 inputs allows for more frequent gamma bursts in CA1. a CA1 gamma bursts before
and after disconnection of SC pathway with their corresponding power spectrum. Note that gamma bursts start appearing more frequently after SC
disconnection (n = 14 slices from 10 animals). b Gamma bursts generated in isolated CA1 mini-slices with a single gamma burst expanded below
with its corresponding power spectrum (n = 41 slices from 28 animals). c Pharmacological isolation of CA1 from CA3 inputs by NBQX (10 µM) and D-
AP5 (50 µM). Note that all activity in CA3 is abolished by NBQX+D-AP5 and only gamma bursts remain in CA1 (n = 8 slices from eight animals).
Subsets below show a gamma burst in CA1 before (left) and in the presence of NBQX+D-AP5. d Similar to anatomical disconnection of CA3 inputs; e
pharmacological isolation of CA1 also causes decrease in intervals between gamma bursts. Averages ± standard error of the mean. **p = o
0.01 signiﬁcance, unpaired Student's t test
Fig. 4 Propagation of CA1 gamma bursts. a Simultaneous ﬁeld recordings from CA3, CA2, and CA1 show gamma bursts are conﬁned to the CA1
where they begin before initiation of CA3 epileptiform events. b Simultaneous ﬁeld recordings from CA1a, CA1b, and CA1c reveal that gamma bursts
in most cases develop in CA1c from where they propagate towards CA1b and CA1a (n = 14 slices from nine animals). c Normal aCSF reversibly stops
the generation of gamma bursts in CA1 mini-slices (n = 5 slices from ﬁve animals). d Perfusion of zero Ca2+ aCSF also reversibly blocks gamma bursts
in CA1 mini-slices (n = 7 slices from ﬁve animals)
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effect could be blocked by applying TGOT in the presence
of the oxytocin receptor antagonist vasotocin (1 µM, Fig.
5i, Table 2).
Discussion
Epilepsy and autism exhibit remarkable comorbidity,
raising the question whether a common mechanism
underlies their development. This might allow shared
interventions and enlarge the spectrum of therapies for
both diseases. We here report, in a hippocampal slice
preparation, an epileptiform activity that consists of bursts
with gamma oscillations similar to those previously
identiﬁed as an underlying cause for behavioral changes in
animal models for autism12. These bursts are carried by
excitatory GABAergic transmission as a result of a change
in Cl− equilibrium potential. We show that treatments,
previously identiﬁed in ASD animal models to target the
Cl− equilibrium potential, are also effective against these
in vitro epileptiform gamma bursts. Consequently, we
found a new potential anti-epileptic role for oxytocin and
identiﬁed the involvement of tonic signaling through
extrasynaptic GABA(A) receptors as a potentially new
target for treating ASD.
The epileptiform bursting activity that we found in the
CA1 of the rat hippocampal CA1 slice preparation
appears to result from a higher concentration in extra-
cellular K+ and is blocked by reducing K+ to physiological
levels (Fig. 4c). Traditionally, high [K+]o causes in in vitro
slices of the hippocampus the generation of epileptiform
events in CA3 that consist of a brief initial sustained phase
(ictal tonic) followed by a prolonged intermittent phase
(ictal clonic) that lasts tens of seconds16,26. Initially these
bursts propagate from CA3 to CA1 via SCs, and
CA1 subsequently developed distinct population dis-
charges at gamma frequency (gamma bursts), which
consistently preceded these events. Similar paroxysms in
CA1 have been reported to result from activity-dependent
accumulation of [K+]o
26–28. Multiple factors such as (i)
dense neuronal packing, (ii) exceptionally low extra-
cellular volume fraction, and (iii) CA1’s inability to
effectively regulate excess [K+]o due to low Na
+/K+
ATPase are thought to contribute toward their genera-
tion28–30. Our experiments suggest a similar [K+]o-
dependent mechanism that, in contrast to previous stu-
dies, depends on synaptic transmission.
In vivo, studies by Bihi et al.31 have shown a fast and
large increase in CA1 extracellular potassium levels fol-
lowing a 5 Hz stimulus to alveus in urethane-anesthetized
animals. Furthermore, in both in vitro and in vivo studies,
epileptiform activity is well known to be able to increase
the extracellular concentration of potassium from basal
levels of 3–5mM to ceiling levels of 9–12mM during
seizures, recruiting and depolarizing more neurons as the
concentration increases32–34. Importantly, the scavengingTa
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Fig. 5 (See legend on next page.)
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of extracellular potassium is a slow process lasting several
seconds which might further lead to prolonged depolar-
izations35,36. In addition, high extracellular potassium
leads to swelling of neurons and glial cells resulting in a
sudden reduction in extracellular space, which can
amplify the extent to which extracellular [K+]o increa-
ses37. In support of this idea, furosemide, a drug known
for reducing swelling, is known to suppress seizures (i)
in vitro slice models of epilepsy (including electrical
kindling in slices, high K+, Zero Mg2+, Zero Ca2+, 4-
aminopyridine-induced and bicuculline-induced sei-
zures.), (ii) in vivo seizure models (kainic acid-induced
and audiogenic seizure-prone animals), and (iii) in human
subjects suffering from intractable seizures (for a review
see ref. 38). Taken together, this suggests that changes in
extracellular K+ can also occur in vivo to play a role in the
generation of bursting activity.
Although glutamatergic afferents from CA3 ﬁrst initi-
ated bursting activity in CA1, anatomical disconnection or
pharmacological blockade with glutamate antagonists
subsequently promoted rather than suppressed the
“gamma bursts” (increasing their frequency from 1/180 to
1/50 s). Similarly, in isolated CA1 “mini-slices,” gamma
bursts developed signiﬁcantly faster than in intact slices
(within ~30 instead of 460 min). This suggests a strong
suppressive/inhibitory inﬂuence from CA3 on the devel-
opment of CA1 gamma bursts. Computational studies
have demonstrated increased [K+]o during ictal tonic and
decreased [K+]o during ictal-clonic periods that are gen-
erated in CA335. Their propagation to CA1 may locally
decrease [K+]o and thus delay the onset of gamma bursts.
In addition, CA3 inputs are usually followed by a strong
inhibitory drive that can increase the threshold for seizure
generation as well28. Together, these processes could
underlie the inhibition of CA1 gamma bursts by CA3.
An increase in gamma frequencies seems, at ﬁrst glance,
incompatible with the excitation/inhibition theory of ASD
as it suggests increased, rather than decreased, levels of
inhibition39. Changes in Cl− equilibrium potential that
lead to excitatory GABAergic transmission could explain
this discrepancy, in that they lead both to decreased
inhibition and increases in gamma bursts. This can be
caused by a high [K+]o, that activates the Na
+/K+/Cl− co-
transporter NKCC140 and/or dysfunction of K+/Cl− co-
transporter KCC2, thereby allowing intracellular Cl−
accumulation11. Blocking NKCC1 with bumetanide
indeed signiﬁcantly suppressed the gamma bursts.
Though the KCC2 activator CLP257 was not efﬁcient,
blocking KCC2 (with bumetanide at higher concentration
than used for NKCC1 or with the speciﬁc KCC2 blocker
VU 0463271) signiﬁcantly reduced the gamma bursts,
suggesting that KCC2 has started working in reverse. In
addition, extrasynaptic GABA receptors can contribute to
increased [Cl−]i as these receptors are highly sensitive to
ambient GABA levels20,41 and their tonic activation21,22
will increase Cl− inﬂow. Incubation with 1 µM picrotoxin,
known to block extrasynaptic but not synaptic GABA
transmission24, indeed caused a signiﬁcantly reduction in
the amplitude of the gamma bursts. To investigate con-
tributions from tonic GABA release, we tested the
involvement of the neuronal GABA transporter GAT-1,
which, under high [K+]o, is known to spill high amounts
of GABA into the extrasynaptic space by operating in
reverse and producing non-vesicular GABA release19,20.
Consistently, we found that blocking GAT-1 also reduced
gamma burst amplitude. Taken together, these results
suggest multiple mechanisms (NKCC1, KCC2, extra-
synaptic GABA(A) receptors, and the GAT-1 transporter)
through which high [K+]o can lead to the accumulation of
[Cl−]i and the development of gamma bursts.
In our study, application of the selective oxytocin
receptor agonist TGOT signiﬁcantly suppressed the CA1
gamma bursts, while these effects were reduced in the
presence of the oxytocin receptor antagonist vasotocin.
Recent studies in several rat models for ASD have shown
increases in [Cl−]i levels and gamma oscillations that can
be reverted by oxytocin through its effects on NKCC1 or
KCC210,12,25. Furthermore, gamma frequency oscillations
in CA1 have been tightly coupled with the ﬁring pattern
of parvalbumin expressing fast-spiking interneurons42
that are highly sensitive to oxytocin. Oxytocin increases
their spontaneous GABA release, thereby depleting
Fig. 5 Characterization of synaptic transmission underlying gamma bursts in CA1 mini-slices. a NBQX (10 µM) and D-AP5 (50 µM) have a mild effect
on the gamma bursts (n = 6 slices from 6 animals). b BMI (20 µM) signiﬁcantly reduced the gamma bursts and completely abolished gamma
frequency activity (n = 8 slices from 6 animals). c Application of NKCC1 blocker bumetanide (10 µM) signiﬁcantly reduced gamma burst in CA1 mini-
slices (n = 8 slices from 6 animals). d, f Higher concentration of bumetanide (50 µM; n = 11 slices from 8 animals) known to block KCC2 and speciﬁc
KCC2 blocker VU 0463271 (10 µM; n = 7 slices from 5 slices) signiﬁcantly affect gamma bursts. e Selective KCC2 activator CLP257 (100 µM) increases
the interburst interval and reduces the peak amplitude, without signiﬁcantly affecting other parameters (n = 6 slices from 6 animals, see Table 2 also).
g Picrotoxin (1 µM) known to speciﬁcally block extrasynaptic GABA(A) receptors strongly attenuates the gamma bursts (n = 6 slices from 5 animals). h
Oxytocin receptor agonist TGOT (0.4 µM) signiﬁcantly reduces gamma bursts (n = 15 slices 9 animals). i The effect of TGOT is reduced in the presence
of speciﬁc oxytocin receptor antagonist vasotocin (1 µM) (n = 6 slices from 5 animals). j Speciﬁc GAT-1 blocker SKF89976A hydrochloride (40 µM)
completely abolishes gamma bursts in CA1 mini-slices (n = 8 slices from 6 animals). In spectrograms, gray trace represents before drug treatment and
black traces represent in the presence of drug
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GABA available for evoked synaptic transmission43. Thus,
if activation of fast-spiking interneurons in the CA1 is
required to trigger seizure onset as it was shown in the
EC44, oxytocin could reduce the gamma bursting by
preventing sufﬁcient GABAergic transmission. Through
both these mechanisms (changes in Cl− equilibrium
potential and decreasing evoked GABA release) the gen-
eration of CA1 gamma bursts may be efﬁciently decreased
by oxytocin.
The increased prevalence of epilepsy in patients with
ASD and the more frequent paroxysmal epileptiform
activity in their EEG has led to the belief that ASD and
epilepsy may be different clinical manifestations of the
same brain pathology. Disturbances in [Cl−]i homeostasis
have been implicated in ASD1–5,7,45 and we here show that
the generation of gamma bursts in the CA1 region are
likely to originate from similar changes in [Cl−]i as a result
of extracellular potassium buildup. It is possible that, as in
our epileptic model, changes in potassium homeostasis
also play a role in ASD. Thus, a number of studies have
recently identiﬁed dysfunctional K+ channels and
impaired astrocytic buffering of extracellular potassium in
ASD. The resulting increase in extracellular potassium
has been proposed a likely trigger for onset of seizures in
autism12,46. Furthermore, a loss of control of CA1 (e.g., by
decreased activity in CA3), in our epileptic model, may
also apply in animal models of autism. Thus, recent
ﬁndings have shown that oxytocin may affect in the CA3
to CA1 projections a change in balance of excitatory vs.
inhibitory projections and it is possible that a decrease in
its signaling (such as the one on which one of the ASD
models is based12 may similarly affect the control of the
CA3 over the CA1 in these models. In addition, our study
shows that drug interventions used against ASD5,9,10,12
can also inhibit these epileptiform gamma bursts. These
ﬁndings raise the question as to how the appearance of
epileptiform gamma bursts might affect normal brain
function and underlie the appearance of symptoms
observed in ASD and thereby the comorbidity with
epilepsy.
Gamma frequencies play an important role in the
communication and synchronization between different
brain regions. The CA1 region is strategically located for
communication between CA3 and EC, and directly
receives afferents from both regions. Clinically, CA3 is
more sensitive to damage than CA147, leading to a loss of
control of epileptiform events in CA148. Under such cir-
cumstances, it is possible that changes in GABAergic
transmission lead to epileptiform discharges enhancing
local activity within CA1. This may underlie high levels of
autistic traits in humans that have been associated with
higher peak gamma frequencies such as better abilities to
discriminate differences in line orientations39. At the
same time, this raises the question whether this enhancedTa
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activity remains able to synchronize through the loop
between CA1 and EC via the subiculum and the tem-
poroammonic pathway49,50. Thus, whereas autism sub-
jects are able to focus on details and recognize these
better, they appear less able to integrate these into
coherent representations (found in visual, auditory, lin-
guistic, and social cues51). It is possible that excitatory
gamma bursts reinforce the emphasis on processing that
takes place locally, but fail to evoke synchronization with
distant regions. Reduced interhemispheric gamma-band
coherence has indeed been observed in ASD and is
associated with less perceptual integration52.
Taken together, we here present an in vitro epileptiform
activity in the hippocampal CA1 that can serve as a new
preparation for understanding the comorbidity between
autism and epilepsy. It suggests an important role for
gamma-oscillatory activity as a basis to start disentangling
the intricate interactions that underlie cause and effect
relationships between the two types of pathologies. From
a clinical perspective, our ﬁrst tests in this preparation
reveal a predictive value for treatments of ASD and epi-
lepsy, showing a new potential for oxytocin as an anti-
epileptic and suggest that extrasynaptic GABA signaling
may be a potential target for the treatment of autism.
Thus, we found that the activity in this in vitro model, in
addition to providing a new entry point to study comor-
bidity between autism and epilepsy, can have predictive
value in testing new drug candidate treatments for both
types of diseases.
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